The drugmaker reported Q2 GAAP earnings per share of $0.24 and revenue of $12.51M, exceeding analyst expectations.
Cipher Pharmaceuticals posted second-quarter GAAP earnings per share of $0.24, surpassing estimates by $0.10. Revenue reached $12.51M, beating forecasts by $0.31M.
Analysts had anticipated EPS of $0.14 and revenue of $12.2M for the period. The company’s results reflect stronger-than-expected performance in its core drug portfolio.
Shares showed limited movement in after-hours trading as investors digested the earnings beat.